Content about SVP research and development

May 11, 2012
Amgen offers testimony at FDA biosimilars hearing

Biotech drug maker Amgen has joined the list of companies offering testimony at a Food and Drug Administration hearing on biosimilars Friday.

THOUSAND OAKS, Calif. — Biotech drug maker Amgen has joined the list of companies offering testimony at a Food and Drug Administration hearing on biosimilars Friday.

March 15, 2012
Late-stage trial of MS drug shows positive results

A drug under investigation by Teva Pharmaceutical Industries and Active Biotech reduced symptoms and progression of disease in patients with multiple sclerosis, according to results of a late-stage clinical trial.

JERUSALEM — A drug under investigation by Teva Pharmaceutical Industries and Active Biotech reduced symptoms and progression of disease in patients with multiple sclerosis, according to results of a late-stage clinical trial.

Teva and Active announced the publication of results of the phase-3 "Allegro" study of oral laquinimod in the March 15 issue of the New England Journal of Medicine. The study was conducted in 24 countries and enrolled 1,106 patients with MS who received 0.6 mg of laquinimod per day or placebo.

October 5, 2011
Schiff names former Bayer Consumer product development exec to R&D post

Schiff Nutrition International on Wednesday named Shane Durkee SVP research and development.

SALT LAKE CITY — Schiff Nutrition International on Wednesday named Shane Durkee SVP research and development.

“We welcome Shane and believe his proven track record in driving nutritional supplements innovation will contribute significantly to accelerating our new product program and organic growth," Schiff president and CEO Tarang Amin said.

November 1, 2010
Amgen R&D chief testifies at FDA biosimilar hearing

Amgen's SVP research and development, Joe Miletich, urged members of a Food and Drug Administration...

THOUSAND OAKS, Calif. Amgen's SVP research and development, Joe Miletich, urged members of a Food and Drug Administration panel to establish approval standards for biosimilars that ensure patient safety and follow a science-based approach.

“Put patients first and sound policy will follow,” Miletich said. “Amgen believes biosimilars have a meaningful role to play in the healthcare system. However, dissimilar — unlike generic drugs — are not identical to the innovative biological products.”